clinical trial · NCT06424444
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Dry Eye DiseaseReproxalap ophthalmic solution (0.25%)Vehicle ophthalmic solution
brief summary
A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap
started
Apr 29, 2024
primary completion
Nov 3, 2024
completion
Nov 3, 2024
last updated
Oct 1, 2025
official title
A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol